MALTONI, ROBERTO
MALTONI, ROBERTO
Altri
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer
2024 Cortesi, M.; Bravaccini, S.; Ravaioli, S.; Petracci, E.; Angeli, D.; Tumedei, M. M.; Balzi, W.; Pirini, F.; Zanoni, M.; Possanzini, P.; Rocca, A.; Palleschi, M.; Ulivi, P.; Martinelli, G.; Maltoni, R.
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab
2022 Palleschi M.; Prochowski Iamurri A.; Scarpi E.; Mariotti M.; Maltoni R.; Mannozzi F.; Barone D.; Paganelli G.; Casi M.; Giampalma E.; De Giorgi U.; Rocca A.
Circulating tumor cells as a tool to untangle the breast cancer heterogeneity issue
2021 Rossi T.; Gallerani G.; Martinelli G.; Maltoni R.; Fabbri F.
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?
2020 Maltoni R.; Palleschi M.; Altini M.; Massa I.; Balzi W.; Ravaioli S.; Tumedei M.M.; Rocca A.; Bravaccini S.
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
2020 Maltoni R.; Palleschi M.; Ravaioli S.; Tumedei M.M.; Rocca A.; Melegari E.; Altini M.; Puccetti M.; Manunta S.; Bravaccini S.
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?
2020 Palleschi M.; Maltoni R.; Sarti S.; Melegari E.; Bravaccini S.; Rocca A.
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience
2020 Palleschi M.; Maltoni R.; Ravaioli S.; Vagheggini A.; Mannozzi F.; Fanini F.; Pirini F.; Tumedei M.M.; Barzotti E.; Cecconetto L.; Sarti S.; Manunta S.; Possanzini P.; Fedeli A.; Curcio A.; Altini M.; de Giorgi U.; Rocca A.; Bravaccini S.
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population?
2018 Bravaccini S.; Ravaioli S.; Amadori D.; Scarpi E.; Puccetti M.; Rocca A.; Tumedei M.M.; Masalu N.; Kahima J.; Pangan A.; Faustine L.; Farolfi A.; Maltoni R.; Bonafe M.; Serra P.; Bronte G.
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations
2017 Rocca A.; Schirone A.; Maltoni R.; Bravaccini S.; Cecconetto L.; Farolfi A.; Bronte G.; Andreis D.
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy
2016 Gennari A.; Amadori D.; Scarpi E.; Farolfi A.; Paradiso A.; Mangia A.; Biglia N.; Gianni L.; Tienghi A.; Rocca A.; Maltoni R.; Antonucci G.; Bruzzi P.; Nanni O.
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer
2015 Rocca A.; Farolfi A.; Maltoni R.; Carretta E.; Melegari E.; Ferrario C.; Cecconetto L.; Sarti S.; Schirone A.; Fedeli A.; Andreis D.; Pietri E.; Ibrahim T.; Montalto E.; Amadori D.
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy
2015 Rocca A.; Andreis D.; Fedeli A.; Maltoni R.; Sarti S.; Cecconetto L.; Pietri E.; Schirone A.; Bravaccini S.; Serra P.; Farolfi A.; Amadori D.
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer
2015 Farolfi A.; Scarpi E.; Rocca A.; Mangia A.; Biglia N.; Gianni L.; Tienghi A.; Valerio M.R.; Gasparini G.; Amaducci L.; Faedi M.; Baldini E.; Rubagotti A.; Maltoni R.; Paradiso A.; Amadori D.
Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors
2013 Farolfi A.; Melegari E.; Aquilina M.; Scarpi E.; Ibrahim T.; Maltoni R.; Sarti S.; Cecconetto L.; Pietri E.; Ferrario C.; Fedeli A.; Faedi M.; Nanni O.; Frassineti G.L.; Amadori D.; Rocca A.